Xilio TherapeuticsXLO
13F holders, Q2 2026 (June 30)1holders
0new positions
0sold out
$9.58avg. 13F price*
At the end of Q2 2026, 1 institutions reported holding Xilio Therapeutics Inc. (XLO) in their 13F filings, unchanged from Q1 2026. 0 opened new positions and 0 sold out. The largest holder was Gilead Sciences, Inc. ($6.2M).
- Company
- Xilio Therapeutics Inc.
- CUSIP
- 98422T100
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2026 → Q2 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
Ownership 1 holders
| Gilead Sciences, Inc. | 0.38% | No change | 650,389 | $6.2M |
"% of holder's portfolio" is XLO's weight in each manager's 13F, not the share of Xilio Therapeutics Inc. the manager owns.